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a b s t r a c t
The ETS superfamily transcription factors Elf5 and Ets2 have both been implicated in the maintenance of
the extraembryonic ectoderm (ExE) of the mouse embryo. While homozygous mutants of either gene
result in various degrees of ExE tissue loss, heterozygotes are without phenotype. We show here that
compound heterozygous mutants exhibit a phenotype intermediate to that of the more severe Elf5/
and the milder Ets2/ mutants. Functional redundancy is shown via commonalities in expression
patterns, in target gene expression, and by partial rescue of Elf5/ mutants through overexpressing
Ets2 in an Elf5-like fashion. A model is presented suggesting the functional division of the ExE region
into a proximal and distal domain based on gene expression patterns and the proximal to distal
increasing sensitivity to threshold levels of combined Elf5 and Ets2 activity.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The trophectoderm cells of the eutherian mammalian blastocyst
give rise to the trophoblast forming the bulk of the foetal portion of
the placenta (Gardner et al., 1973). In mice actively proliferating
trophoblast cells are conﬁned to the region overlying the inner cell
mass. This region is termed the polar trophectoderm and expands
into the blastocyst cavity after implantation at embryonic day
(E) 4.5 (Copp, 1979). By E5 this proliferative region occupies the
“top” (closest to implantation site) half of the egg cylinder and is
termed the extraembryonic ectoderm (ExE). The bottom half of the
egg cylinder ectoderm is the embryonic ectoderm that will give rise
to the embryo proper. The junction between the embryonic
ectoderm and ExE can be easily morphologically distinguished by
virtue of a circumferential constriction. We shall here use this
constriction landmark as a reference point, referring to trophoblast
close to it as proximal, distant trophoblast as distal. The ExE is
connected on the implantation (distal) side to a stalk of trophoblast
cells termed the ectoplacental cone (EPC). The EPC attaches the
conceptus to a mass of fully differentiated trophoblastic giant cells
which mediate the early endometrial interactions. The proximal to
distal arrangement of ExE-EPC-giant cells is maintained until
midgastrulation, when the extraembryonic mesoderm and amniotic
cavities push the ExE distally away from the embryo proper
(Kaufman, 1995). The resultant ﬂattened ExE lined with extraem-
bryonic mesoderm is termed the chorion. Trophoblastic stem (TS)
cells, dependent on FGF and Nodal/Activin signalling, can be
isolated from polar trophectoderm and ExE but not EPC tissue
during these stages (Tanaka et al., 1998; Uy et al., 2002). These TS
cells, resembling from their gene repertoire ExE, can be differen-
tiated in vitro into cells resembling chorionic derivatives such as
syncytiotrophoblasts, EPC derivatives such as spongiotrophoblasts
as well as into giant cells.
While numerous genes have been implicated in this sequence of
trophoblast developmental events (Simmons and Cross, 2005), two
are characterised by speciﬁcally being required for the early main-
tenance of the proliferative ExE. These are Elf5 and Ets2 (Yamamoto
et al., 1998; Donnison et al., 2005; Georgiades and Rossant, 2006;
Wen et al., 2007; Odiatis and Georgiades, 2010; Polydorou and
Georgiades, 2013). Notably, both these genes code for proteins
belonging to the 26 proteins making up the superfamily of ETS
transcription factors (Blake et al., 2014). Loss of function of either
factor results in an incompletely penetrant phenotype where, in the
most severe form all (Elf5) or most (Ets2) of the ExE tissue is lost by
E6.5, the start of gastrulation (Donnison et al., 2005; Georgiades and
Rossant, 2006). This leads to an early arrest of trophoblast devel-
opment and embryonic lethality a couple of days later. Both genes
show exclusive trophoblast expression until at least late gastrulation
stages and mutants can be rescued in chimeras via extraembryonic-
only expression (Yamamoto et al., 1998; Donnison et al., 2005;
Georgiades and Rossant, 2006). Furthermore no TS cells can be
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derived from loss of function mutants for either gene, indicating an
essential requirement for both factors. In view of the similar loss of
function phenotype and the observation that the consensus binding
sites of Ets2 and Elf5 are nearly identical, (accGGAagt) versus
(cccGGAagt) (Wei et al., 2010), we hypothesised that these proteins
may be able to at least partially compensate for each other.
Results
An early developmental epistatic relationship between Elf5 and Ets2
Neither Elf5 nor Ets2 mutants display an embryonic phenotype in
the heterozygous condition. However, when we crossed Elf5þ/
with Ets2þ/ animals, we noted that 10% of deciduas were empty at
E14.5 (Table 1). Similarly, at E10.5 nearly 10% of deciduas were empty
or contained a severely retarded embryo. This strongly suggests that
Ets2 and Elf5 are synergistically epistatic, that is, the compound
phenotype is more severe than the sum of the individual phenotypes.
This synergistic effect seemed to exist already at E6.5 (35% observed
small embryos from compound heterozygous crosses relative to the
expected 30%, as detailed in Table 1), but was not statistically
signiﬁcant at this stage. We estimate the penetrance of an Elf5þ
/Ets2þ/ phenotype to be 40% based on the E10.5 and E14.5 data
(calculation in Table 2). By assuming this degree of penetrance we
could explain the skewed proportions of genotyped pups obtained
when crossing Elf5þ/ with Ets2þ/ animals (Table 2).
An Elf5 Ets2 interaction prior to gastrulation
As the number of retarded/small embryos obtained from hetero-
zygous crosses at the start of gastrulation (E6.5) tended to be higher
than expected (Table 1), we investigated this effect in more detail by
subjecting E6.5 Elf5þ/Ets2þ/ embryos to whole mount in situ
hybridisation. In a subset of embryos conﬁrmed to be doubly
heterozygous mutants, defective trophectoderm development was
apparent. Oct4 (Pou5f1) and Cripto (Tdgf1) mark the embryonic
ectoderm (Rosner et al., 1990; Ding et al., 1998). In E6.5 Elf5þ
/Ets2þ/ embryos, Oct4 and Cripto staining extended close to the
ectoplacental cone (EPC), indicating a severe loss of ExE tissue as
also seen in Elf5/ or Ets2/ mutants (Fig. 1). This effect was
conﬁrmed by additional staining for Ascl2 (Mash2), which marks the
EPC and ExE distal to the embryonic–extraembryonic border (DiExE;
see later for more detailed descriptions). In wild type or singly
heterozygous embryos the embryonic ectoderm, marked by Cripto,
and the DiExEþEPC, labelled by Ascl2 staining, are separated by the
proximal ExE tissue (Fig. 1D, left embryo). However in the Elf5þ
/Ets2þ/ embryo the Cripto staining abuts the Ascl2 positive
domain. The Elf5/ and Elf5/Ets2þ/ phenotypes are more
severe than the double heterozygotes in that Ascl2 expression is
nearly completely lost (Fig. 1D but see also Fig. 7). We conclude that
while embryos heterozygous mutant for either Elf5 or Ets2 are
normal, doubly heterozygous embryos show an incompletely pene-
trant phenotype whereby the proximal extraembryonic ectoderm is
lost by the start of gastrulation. This indicates a positive epistatic
interaction between these two transcription factors.
Overlap of Elf5 and Ets2 targets in TS cells
An epistatic interaction of Ets2 and Elf5 would be expected if these
transcription factors shared common target sites. This scenario is
plausible as their DNA recognition consensus sequences are similar
(Choi and Sinha, 2006; Wei et al., 2010). We have previously
determined potential target genes of Elf5 using a siRNA knockdown
approach in TS cells (Pearton et al., 2014) and now applied a similar
strategy to Ets2 so as to determine commonalities. Two different Ets2-
siRNA were able to knock down Ets2 RNA levels by over 80% in TS
cells after 48 h treatment, relative to control siRNA-treated or
untreated cells (Fig. 2A). Screening of Affymetrics arrays revealed a
set of 15 genes misregulated by at least 2-fold after treatment with
either of the Ets2 siRNAs (Table 3). Comparing the misregulated genes
with our previously published Elf5 target gene dataset revealed four
genes to be affected in a similar fashion by either Ets2 or Elf5 down
regulation (Table 4). We veriﬁed the Ets2 targets by quantitative
RT-PCR using numerous repeats (Fig. 2A and B). This analysis casted
some doubt on the authenticity of Ascl2, Emp1, Lgals3 and Mbnl3 as
misregulated genes (Fig. S1), but supported the microarray results of
the other nine genes including three that were also Elf5 targets
(Fig. 2A). Unlike what is seen after Elf5 down regulation, none of the
genes downregulated after loss of Ets2 activity is known to be
involved in trophoblast stem cell maintenance (Pearton et al., 2011),
a result conﬁrmed by PCR for the trophoblast stem cell markers Cdx2,
Eomes, ERRβ and Sox2 (Fig. 2C and D). Importantly no effect is seen on
Elf5 (Fig. 2D) nor some of the Elf5 targets (Fig. 2C), excluding the
possibility that Ets2 acts simply via Elf5 down regulation. Similarly,
Elf5 knock down had no effect on Ets2 expression (Fig. 2E), as also
previously shown (Pearton et al., 2014). Since Ets2 and Elf5 do not
affect each other's expression levels and as even a single shared gene,
let alone three, would not be expected by chance if the target sets
Table 1
Frequency of defective embryos (small or resorbed) from heterozygous crossesa.
Stage nb Observed 95% Conf. limits Expected c P(χ2) d
E14.5 e 122 12 (10%) 5.2–17% 0 (0%) 1.4E-06
E10.5 e 39 3 (8%) 1.6–21% 0 (0%) 0.049
E6.5 f 211 73 (35%) 28–41% 63 (30%) 0.17
a See supplementary Table S1 for details.
b Number of deciduas.
c Expected numbers on assumption that all embryos having Elf5/ and/or
Ets2/ genotype will be defective and single heterozygous animals will show no
defects.
d Probability that difference between observed and expected is signiﬁcant.
e Only double heterozygotewild type or Elf5þ/  Ets2þ/ crosses.
f Compound crosses (Table S1).
Table 2
Reduced frequency of double heterozygous pups (n¼254) from (Elf5þ/ , Ets2þ/)
(wild type) matings (129 strain).
Genotype Observed
number
of pups
(%)
95%
Conﬁdence
limits (%)
Expected
if
genotype
were
irrelevant
P(χ2)
that
diff is
signif.
expected if
60% of Elf5þ/
 ; Ets2þ/
pups survive a
P(χ2)
that
diff is
signif.
Elf5þ/þ
Ets2þ/
þ
84 (33%) 27–39% 64 (25%) 71 (28%)
Elf5þ/-
Ets2þ/
þ
71 (28%) 22–34% 64 (25%) 71 (28%)
Elf5þ/þ
Ets2þ/

65 (26%) 20–31% 64 (25%) 71 (28%)
Elf5þ/
Ets2þ/

35 (14%) 10–19% 64 (25%) 0.0002 42 (17%) 0.24
a The assumption of 40% lethality of Elf5þ/ ; Ets2þ/ pups is derived from
Table 1, where an overall 10% loss of embryos, not attributable to Elf5/ or
Ets2/ genotypes, was observed. Thus, if original number of embryos is x,
number of embryos conceived of each of 4 genotypes (g) would, according to
Mendelian statistics, be (x/4). The observed number of embryos surviving (n)¼0.9x
(Table 1). If we assume that all dead (unborn) embryos are derived from one
genotype, (Elf5þ/ , Ets2þ/), then the surviving pups with this phenotype would
be (g0.1x)¼(x/4)0.1x¼0.15x. This corresponds to 0.15x/0.9x¼1/6th (¼17%) of
pups born, reﬂecting a 60% survivability (0.15x/0.25x).
M. Donnison et al. / Developmental Biology 397 (2015) 77–8878
were independent (P¼1.6E11), we conclude that Ets2 and Elf5 exert
their effect via partially overlapping gene pathways.
Complementary expression of Ets2 and Elf5 in an in vitro assay of
trophoblast differentiation
The partial commonality of gene targets warranted a further
exploring of similarities and differences in the expression pattern
and levels of Ets2 and Elf5 transcripts. Trophoblast stem cells can
be kept in an undifferentiated state in vitro in the presence of FGF
and Activin/Nodal signalling (Tanaka et al., 1998; Erlebacher et al.,
2004; Natale et al., 2009). Upon growth factor removal (e.g. by
growth in the absence of exogenous FGF and conditioned med-
ium), TS cells differentiate into the two main derivative lineages,
namely syncytiotrophoblasts and giant cells. We mapped Ets2 and
Elf5 transcription in relation to other markers during this differ-
entiation assay in a geometric series of time points (Fig. 3). Cdx2
expression was lost in this assay within 2 days reﬂecting the loss of
trophoblast stem cell potential. Spry4, which has not previously
been described as a TS cell marker but which we found to be lost
upon Ets2 inactivation, exhibited the most dramatic response to
growth factor removal, being silenced within 6 h. In other tissues,
Spry4 is known to be highly dependent on FGF signalling and is a
negative feedback inhibitor of this pathway thereby limiting the
range and duration of FGF signals (Hayashi et al., 2009; Yu et al.,
2011). Similarly, the “stem”-ness factor Sox2, known to be highly
FGF dependent in ES as well as TS cells (Adachi et al., 2010),
dropped to below half its starting levels within 6 h of growth
factor removal, followed 6 h later by the loss of the trophoblast
stem cell marker Eomes. In contrast, Elf5 as well as Fgfr2 exhibited
a 12 h delay before transcription levels were reduced. Interest-
ingly, Elf5 RNA levels reached a steady state of around 20%
maximal levels by 24 h which was maintained thereafter. The
transient differentiation marker Ascl2 was upregulated upon
growth factor removal, peaking between 12 and 48 h to then
precipitously vanish as trophoblasts differentiated further. PlacI
which increased after 48 h of Ets2 knockdown, also behaves as a
transient differentiation marker in the growth factor removal
assay, peaking 4 days post growth factor removal. In contrast to
Elf5, Ets2 levels only increased after 2 days of growth factor
removal along with the differentiation markers Tpbpa and Secretin.
In the presence of retinoic acid trophoblast differentiation in vitro
can be directed preferentially toward a giant cell fate at the
expense of syncytiotrophoblasts (Yan et al., 2001). Ets2 levels
increased upon RA addition whereas, as predicted, the activation
of the syncytiotrophoblast marker Tpbpa was severely squelched
under such conditions (Fig. 3). Unlike differentiation markers
though, Ets2 levels are signiﬁcant in undifferentiated TS cells
(20% of maximal levels seen after 7 days of differentiation). Thus
while Elf5 dominates the non-differentiated and Ets2 the differ-
entiated periods in this assay, both are substantially expressed in
the reciprocal periods.
Overlapping but distinct expression pattern of Ets2 and Elf5 in vivo
At E5.5, shortly after the ExE has been formed, Ets2 and Elf5 are
expressed in this tissue in an overlapping pattern (Fig. 4). A day
later though, the pattern of expression of these genes is largely
complementary with Elf5 expression located predominantly in the
ExE region whereas Ets2 is seen predominantly in the EPC and
giant cell regions, which are composed of more differentiated cells
(Fig. 5). To characterise these regions in more detail, we analysed a
series of whole mount in situ hybridisations for various tropho-
blast genes (Fig. 5A and B). The extent of staining was measured in
relation to the clearly discernable embryonic/extraembryonic
ectoderm constriction (EEC). The developmental stage of the
embryo's trophoblast was estimated by measuring the size of
the ExE region. The ExE extends from the EEC to the distal
isthmus-like constriction separating the roughly rugby-ball
shaped egg cylinder (embryonic ectodermþExE) from the over-
laying cone/irregular mass of trophoblast cell (EPC and, more
distally, giant cells).
Analyses of the gene expression patterns for similarly staged
embryos revealed Elf5 (as well as Fgfr2) expression to extend
Fig. 1. Double heterozygous embryos (Elf5þ/; Ets2þ/) lose the ExE. Whole
mount in situ hybridisation of compound mutant E6.5 embryos. The embryonic–
extraembryonic junction is identiﬁed by white, and the ExE-EPC constriction/
isthmus by blue, triangles. The region delimited by the white and blue triangles is
the ExE. All three Elf5þ/Ets2þ/ mutants shown (Panels B and middle embryo
in panels C, D) have lost variable amounts of the ExE, though less than mutant
embryos deﬁcient for three of the four Elf5þEts2 alleles (right embryos in C, D).
Embryos are orientated with distal trophoblast (implantation side) at top of panels.
Scale bar is 100 mm.
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Fig. 2. Expression levels of genes after Ets2 or Elf5 down regulation in TS cells. (A–D) Average gene expression levels in TS cells after 48 h of treatment with either Ets2 siRNAs
1 or 2, Control siRNA (siC) or no treatment (NT). Levels shown are relative to the geomean of three housekeepers with three PCR repeats per sample and 15 samples for each
treatment. Expression of: (A) Ets2 itself and Elf5 target genes, (B) Ets2 but not Elf5 target genes, (C) Elf5 but not Ets2 target genes and (D) TS genes. (E) Elf5 and Ets2
expression after Elf5 knock down with Elf5 siRNA 1 and 2. Each treatment was repeated ﬁve times. Different letters represent statistically signiﬁcant differences (Po0.05).
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beyond that of the TS markers Cdx2, Sox2, Spry4 and Eomes, into a
distal ExE area that expresses Ascl2 (Fig. 5A and B). The average
proximal–distal extent of the Elf5-positive domain is 86710 mm.
This region lies proximal to intense Ets2 staining which starts
99715 mm distal to the EEC. If the in situ hybridisation staining
reaction is allowed to proceed longer, weaker Ets2 staining can
also be clearly discerned right up to the EEC. The proximal border
of intense Ets2 expression is not signiﬁcantly different from that of
Plac1 and Secretin within the resolution of these measurements
(Fig. 5B; see also Fig. 9A). In contrast to those genes however, the
distal border of Ascl2 tends not to encompass the entire giant cell
area (Fig. 5B), though we have not quantitated this as that tissue is
often lost or damaged during preparation/hybridisation. Spry4,
which is downregulated within two days of Ets2 knockdown in TS
cells, marks the proximal ExE.
We conclude that after an initially similar expression proﬁle at
E5.5, the predominant region of Elf5 and Ets2 expression is
complementary as opposed to overlapping, though Ets2 also is
expressed in the proximal ExE domain albeit at lower levels. This
resembles the temporal pattern in the TS differentiation assay if
spatial proximity is set to equate early timing (discussed in Fig. 9).
Are Elf5 and Ets2 functionally equivalent?
The similarity in target genes and phenotype coupled with the
known near identity in terms of DNA binding function of Elf5 and
Ets2 suggests that these proteins may be functionally equivalent
with the main difference being one of dosage and spatial expres-
sion pattern. In undifferentiated TS cells, Ets2 mRNA levels were
about 10% of those of Elf5 (Fig. 2A, D, and E). Similarly, in the ExE of
E6.5 embryos, Ets2 expression was only 25% of that of Elf5 (Fig. 6E).
While these Ets2 transcript levels are insufﬁcient to mask the Elf5
loss of function phenotype, would higher levels result in a rescue
thereby indicating a functional equivalency? As the Elf5 enhancer
has been well characterised (Pearton et al., 2011), we used a
transgenic strategy to express Ets2 in an Elf5-like fashion, adding
an IRES-eGFP cassette so as to be able to verify lines exhibiting an
Elf5 expression pattern (Fig. 6A). The Ets2-IRES-GFP construct was
shown to yield Ets2 protein in vitro (Fig. 6D). Microinjection of the
Elf5-Ets2iGFP construct yielded four transgenic lines, each show-
ing ExE-speciﬁc (proximal and distal) expression (Fig. 6B and C).
Quantitation in E6.5 ExE tissue indicated that lines 3 and
4 expressed the highest levels of Ets2 (47% and 63% respectively
of Elf5, Fig. 6E). Elf5-Ets2iGFP transgenic (tg) lines 3 and 4 were
ﬁrst bred onto strain 129, in which the Elf5 loss of function
phenotype is more severe (Donnison et al., 2005), before crossing
against Elf5þ/ mice.
On the 129 strain, neither type 1 (no ExE tissue) nor the less
severe type 2 Elf5 mutant embryos show signiﬁcant Ascl2 expression
(Figs. 1D and 7B,C; and data not shown). However, expressing
additional Ets2 under the control of the Elf5 ExE-enhancers restored
Ascl2 expression in Elf5/ embryos, even though such expression
was unable to fully rescue the ExE tissue (2/2; line 4; Fig. 7E and F).
The loss of the ExE in Elf5 mutants leads to defects in gastrulation,
presumably due to the absence of ExE-derived convertases that
diffuse into the adjacent embryonic ectoderm to activate Nodal (Beck
et al., 2002; Donnison et al., 2005). At E7.5, Cdx2 can be used as a
marker for posterior extraembryonic mesoderm and its expression
straddles the posterior EEC (Fig. 8A). In Elf5/ (3/3) as well as in
Elf5/; Elf5-Ets2iGFPline3 embryos (2/2), Cdx2 expression is lost
(Fig. 8E). However, in Elf5/; Elf5-Ets2iGFPline 4 embryos, we
noted Cdx2 expression in two out of three embryos (Fig. 8B–D), even
Table 3
Genes up- or down-regulated per affymetrics assay in TS cells by at least twofold after 48 h treatment with Ets2-siRNA1 as well as after treatment with Ets2-siRNA2, relative
to Control siRNA treatment; (NT, no treatment).
Gene Gene title ID si1/siCon P si2/siCon P siCon/NT P
Vim vimentin 1456292_a_at 3.73 0.01 2.51 0.04 2.15 0.12
Npm3 nucleoplasmin 1423522_at 2.73 0.00 2.10 0.00 1.13 0.62
Zic3 zinc ﬁnger protein of the cerebellum 3 1423424_at 2.69 0.00 2.33 0.00 1.14 0.21
Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 1417542_at 2.59 0.00 2.29 0.00 1.17 0.16
Zic3 zinc ﬁnger protein of the cerebellum 3 1438737_at 2.56 0.00 2.31 0.00 1.13 0.44
Ets2 E26 avian leukemia oncogene 2, 30 domain 1416268_at 2.36 0.00 2.86 0.00 1.02 0.80
Spry4 sprouty homolog 4 1445669_at 2.31 0.00 2.25 0.00 1.12 0.54
Rgs16 regulator of G-protein signaling 16 1426037_a_at 2.30 0.00 2.61 0.00 1.06 0.59
Prss46 protease, serine 46 1429646_at 2.27 0.00 2.30 0.00 1.08 0.51
5430416N02Rik RIKEN cDNA 5430416N02 gene 1439071_at 2.23 0.00 2.25 0.00 1.09 0.62
Lgals3 lectin, galactose binding, soluble 3 1426808_at 2.00 0.00 2.04 0.00 1.06 0.38
Plac1 placental speciﬁc protein 1 1417553_at 2.04 0.00 2.71 0.00 1.42 0.15
Emp1 epithelial membrane protein 1 1416529_at 2.06 0.01 2.01 0.02 1.33 0.33
Unknown 1445626_at 2.17 0.00 2.07 0.00 1.03 0.76
Lpl lipoprotein lipase 1415904_at 2.36 0.00 2.44 0.00 1.24 0.23
Mbnl3 muscleblind-like 3 1434678_at 2.36 0.00 2.01 0.00 1.14 0.08
Ascl2 achaete-scute complex homolog 2 1422396_s_at 2.59 0.00 2.48 0.00 1.37 0.09
Table 4
Comparison of Ets2 and published Elf5 target genes.
Targets
of
Gene names a Number Pb
Ets2 Vim, Npm3, Zic3, Rps6ka2, Spry4, Rgs16, Prss46, 5430416N02Rik, Lgals3, Plac1, Emp1, 1445626_at, Lpl, Mbnl3, Ascl2 15
Ets2 and
Elf5
Prss46, Vim, Zic3, Lgals3 4 3.0E126
Elf5 c Fndc3c1, Prss46, Cyr61, Hs3st3b1, Zic3, Dcaf12L1, Sox2, Ssbp2, Sox3, Pdk1, Hmga2, Bex1/4, Synpo2L, Mme, Pkdcc, Vim, Sh3bgrl, Lin28A,
Ppap2B, 1190003J15Rik, Adk, Cyp11A1, Col4A1, Serpinb9b, Lgals3, Hand1, Ly6a, Krt7, Csrp1, Tgm2, Secretin
31
a Genes arranged from most downregulated (italic) to most upregulated (italic bold) with common targets of Ets2 and Elf5 underlined.
b Number of expected common genes if independent¼(15n31/22,000)¼0.021, with the number of genes on the affymetric array¼22,000. Note that even one
overlapping target bears a signiﬁcance level of 1.6E11 (Pearson).
c From Pearton et al. (2014), genes were included from 1.8 fold change in expression after 24 h of siRNA treatment.
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though these embryos were developmentally impaired. The incom-
plete rescue of mesodermal Cdx2 initiation in line 4, which expressed
higher levels of Ets2, and absence of rescue in line 3, suggests that
the dosage of Ets2 achieved in these Elf5 deﬁcient embryos is critical.
We conclude from the in vivo rescue experiments that Ets2 can
partially functionally substitute for Elf5.
Discussion
A subdivision of the ExE
Shortly after the start of gastrulation, at E6.5, the trophoblast is
composed of three regions. The region extending distally from the
EEC and enclosing the extraembryonic half of the central cavity
(coelom) is termed the extraembryonic ecoderm. The ExE merges
into a stalk-like structure capping the egg cylinder, called the
ectoplacental cone. The EPC in turn seamlessly merges into the
irregular clump of tissue that consists of predominantly secondary
giant cells which invade the maternal uterine endothelium. We
have measured here the proximal–distal expression of numerous
trophoblast genes as summarised in Fig. 9A. Based on this analysis
we propose a subdivision of the ExE into two distinct regions,
namely a proximal and distal portion. The proximal region, the
PrExE, is characterised by unique expression of the trophoblast
stem cell genes Cdx2, Sox2 and Eomes as well as Spry4 and the
absence of Ascl2 expression. This region extends to about 50 mm
from the EEC. The distal ExE expresses the pan-ExE markers Elf5,
FgfR2 and Ets2 (the latter at lower levels) as well as Ascl2 but not
the previously listed trophoblast stem cell markers. This region is
also 50 mm long. The EPC, in turn, can be molecularly distinguished
from the DiExE by unique expression of differentiation markers
such as Plac1, Secretin and intense Ets2 expression.
This gene expression-based subdivision of the ExE into two
halves likely represents a shift from embryonic ectoderm-
dependent cells to independent cells. Indeed the EmE is the source
of secreted Nodal and Fgf4, which have been shown in explant
studies to be required for ExE function (Guzman-Ayala et al.,
2004). The range of signalling is complicated by morphogen
stability and diffusibility as well as other factors (Le Good et al.,
2005; Muller et al., 2012). For example in zebraﬁsh the two
Nodal analogues Cyclops and Squint exhibit a concentration of
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Fig. 4. Overlapping expression of Ets2 and Elf5. Whole mount in situ hybridisation
showing expression of: (A) Ets2 and (B) Elf5 in the ExE at E5.5. Bar, 100 mm.
Fig. 3. Temporal activation of trophoblast speciﬁc genes in TS cells after growth
factor removal-induced differentiation with and without RA addition. TS cells were
grown for the indicated number of hours (2 geometric series of time points) in
the absence of growth factors (via removal of conditioned medium and exogenous
Fgf4), so as to induce differentiation. Each timepoint is based on three samples with
each sample measured by quantitative real time RT-PCR in triplicate and normal-
ised against the geomean of three housekeepers. Gene expression was also
measured after 96 and 128 h in the absence of growth factors but in the presence
of 1 mM all trans retinoic acid (RA; open circles) which should predispose TS cells to
differentiate into giant cells (Yan et al., 2001). For each gene, levels shown are
percentages of the maximal expression observed.
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20% and 40% from the source border at 50 μm (Muller et al., 2012),
which is the length of the morphogen-dependent portion of
the ExE, namely the PrExE. Conversely the range of embryonic
ectoderm-derived Fgf4 is likely to be kept in check by the Ets2-
dependant Spry4 inhibitor, the expression of which (in the PrExE)
is itself a readout of FGF signalling (Hayashi et al., 2009). It should
be noted that at early stages of ExE development such as E5.5, the
entire proximal–distal size of the ExE is only 5072.2 μm (Fig. 5A)
and thus would be expected to be under the inﬂuence of epiblast-
derived morphogens. In line with this, the E6.5 PrExE-speciﬁc
genes are expressed over the entire E5.5 ExE. The idea of growth
factor dependence is recapitulated in our time course analyses of
TS cells after morphogen removal. Removal of ectopic FGF and
conditioned medium-derived Activin/Nodal from undifferentiated
TS cells causes a rapid loss of Cdx2, Sox2, Eomes and Spry4 (50–
100% reduction within 6–12 h; see Fig. 9A for summary) while the
pan-ExE markers Elf5 and Fgfr2 are still unaffected. The next two
time slots (12 and 24 h) represent the progression of differentia-
tion, mirroring the DiExE gene expression state with continued
Elf5 and Fgfr2 expression and upregulation of Ascl2. Notably Ets2
expression is detectable but low, then rises after 48 h in the “EPC”
Fig. 6. Overexpressing Ets2 in an Elf5-like fashion: (A) pElf5-Ets2iGFP expression
construct containing 19 kbp of Elf5 genomic sequence to drive expression of the
bicistronic Ets2-IRES-GFP cassette in an Elf5-like fashion. The arrow indicates the
Elf5 transcriptional initiation site, red boxes are polyA sequences. (B) and
(C) Overexpression of Ets2 protein in pElf5-Ets2iGFP transgenic embryos could
be monitored in vivo with ﬂuorescent microscopy to detect co-cistronic GFP (B, line
4, E5.5; C, line 3, E6.5 embryos). Scale bars, 50 μm. (D) The Ets2-IRES-GFP cassette
was tested for the generation of functional Ets2 protein via Western blot of primary
bovine embryonic ﬁbroblast cells overexpressing pCAG-Ets2-IRES-GFP and using
anti Ets2 antibody. (E) For each transgenic pElf5-Ets2iGFP line, E6.5 ExE were
microdissected and transgenic (tg) and wild type (wt) fragments from the same
“litter” pooled to determine Ets2 and Elf5 mRNA levels via triplicate real-time RT-
PCR. Only lines 3 and 4 showed substantial (42 fold) increases over wild type
levels (dashed line) in Ets2 mRNA expression. Numbers of embryos pooled were
(line-wt/tg): line1-3/1; line2-4/5; line3-7/3; line4-4/3.
Fig. 5. Expression limits of trophoblast genes in relation to the embryonic/
extraembryonic ectoderm constriction (EEC) and ExE/EPC borders: (A) Each black
bar represents the expression domain, as determined by whole mount in situ
hybridisation, for the indicated gene in an E5.5–E6.5 embryo. Zero represents the
EEC whereas the right end of the blue bar indicates, in mm, the length of the ExE
domain as judged by the distal ExE/EPC isthmus. For Ets2, only the intense
expression was quantiﬁed. (B) Example of a typical E6.5 embryo WMISH staining
pattern for each gene as shown in the panel to the left. White triangles indicate the
Epi/ExE constriction, black the distal/proximal staining limit and blue the distal
(relative to the epiblast or embryonic ectoderm) end of the embryo. The scale bar is
100 mm.
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phase of this TS differentiation progression. This is similar to its
E6.5 spatial pattern of low in the PrExE and DiExE, but high in the
EPC (Fig. 9A).
The role of Elf5 and Ets2 in relation to the ExE and each other
In line with its stronger expression in the EPC, the Ets2 knock-
out was initially described as having a strong effect on this tissue
with a reduction in EPC size and the occurrence of increased
apoptosis (Yamamoto et al., 1998). A later study revealed earlier
defects with variable reductions in the size of the ExE from highly
reduced (type I) to nearly normal (type II phenotype) (Georgiades
and Rossant, 2006). Loss of the ExE is also a characteristic of Elf5
deﬁcient embryos. Again the defect shows some variability with a
milder type II phenotype retaining sufﬁcient extraembryonic
trophoblastic tissue to allow the ExE-dependent process of meso-
derm induction. Interestingly though, while all Ets2mutants retain
Ascl2 positive tissue as well as at least some ExE tissue between
the EEC and the Ascl2-positive domain (Georgiades and Rossant,
2006) our results here show that all Elf5 mutants, even those
retaining some trophectoderm within the egg cylinder, lose or
severely down-regulate Ascl2 expression. Embryos heterozygous
for either Elf5 or Ets2 exhibit no phenotype. Interestingly though,
we found that the compound heterozygotes variably lost the ExE
similar to homozygous Elf5 or Ets2mutants. Knock-down or loss of
function of either gene in TS cells had no effect on the expression
of the other (Fig. 2 and (Wen et al., 2007; Pearton et al., 2014)).
There is also no in vivo compensation of Ets2 expression upon loss
of one Elf5 allele (Fig. S2). Thus to explain why the loss of any two
of the four alleles of Elf5þEts2 leads to a similar phenotype, we
explored the possibility that Elf5 and Ets2 were at least partially
redundant in a dose dependent fashion.
In support of such redundancy is the overlap in misregulated
gene sets when either gene is knocked down in TS cells. Such
overlap is not unexpected considering that both genes belong to
the same superfamily of ETS transcription factor and though they
belong to different subfamilies, with Ets2 having an ETS-Class I
and Elf5 a Class 2 DNA-binding afﬁnity, their DNA recognition
sequences are very similar (Wei et al., 2010). Secondly, both genes
are expressed in similar domains at E5.5. Although by E6.5 the
domain of maximal expression is complementary, Ets2 is also still
expressed in the ExE, albeit at relatively low levels. Third, though
the expression levels are reciprocal, both genes are expressed at
measurable levels during TS cell differentiation.
However the strongest evidence for at least a partial in vivo
redundancy of Elf5 and Ets2 comes from our rescue experiment,
where additional Ets2 is expressed in an Elf5-like fashion in an Elf5
deﬁcient background. While such embryos were not normal, Ascl2
expression was restored and sufﬁcient trophectodermal tissue gener-
ated to allow for posterior (Cdx2-positive) mesoderm induction.
We propose the following model to account for the observa-
tions (Fig. 9B). During early stages of trophoblast differentiation,
Fig. 7. Rescue of Ascl2 expression in Elf5 knockout embryos by Ets2: (A–F) Whole mount in situ hybridisation of Ascl2 in E6.5 embryos in control embryos (Elf5þ/þ or þ/)
and in Elf5 deﬁcient embryos with (tg) or without pElf5-Ets2iGFP (line 4). White triangles show the EEC (Epi/ExE constriction), blue ones the distal end of the ExE. The scale
bar is 100 mm.
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represented by undifferentiated polar trophectoderm, most of the
E5.5 ExE and speciﬁcally the PrExE of E6.5 embryos, as well as TS
cells, Elf5 activity is required so as to prevent precocious differ-
entiation (Pearton et al., 2014). Ets2, expressed at lower levels than
Elf5 and potentially only able to partially substitute for Elf5 in the
regulation of its target genes, nevertheless contributes an Elf5-like
activity (this difference in activity is shown by shorter bars for Ets2
in Fig. 9B). This Elf5-like activity is necessary as loss of both Ets2
(but not one) alleles results in an early reduction in the number of
progenitor cells of the PrExE. Thus PrExE markers such as Cdx2 and
Sox2 are lost in Ets2/ embryos (Georgiades and Rossant, 2006)
and Spry4 downregulated after knockdown in TS cells (shown
here). We interpret the retention of Ascl2 in such embryos to mean
that the DiExE is retained sufﬁciently long to allow for Ascl2
expression in remaining DiExE and/or EPC tissue. This is supported
at least in type II Ets2 mutants where the DiExE marker Elf5 is
expressed at E6.3 but lost by E6.7 (Polydorou and Georgiades,
2013). Conversely, while full Ets2 activity is able to mask the effect
of losing one Elf5 allele, it cannot compensate for losing both Elf5
alleles. The Elf5/ embryos appear not to form either the PrExE
or the DiExE as shown by absence of the pan-ExE markers Elf5,
Fgfr2 (Donnison et al., 2005) and the DiExE marker Ascl2 (shown
here). The loss of Ascl2, even though such deﬁcient embryos retain
EPC-like tissue which would normally also express Ascl2, suggests
that in such embryos the EPC is abnormal as well. We propose that
the greater severity of the Elf5/ phenotype (compared to the
Ets2/) is directly attributable to the lower overall Elf5-like
dosage in these embryos. The overall dosage idea would thus
predict that combining a single Elf5 allele with a single Ets2 allele
would display an intermediate phenotype (Fig. 9B). This is seen in
Fig. 8. Rescue of posterior mesodermal Cdx2 expression in Elf5 knockout embryos by Ets2: (A–E) Whole mount in situ hybridisation of Cdx2 at E7.5 in a control embryo
(A, Elf5 þ/) and in Elf5 deﬁcient embryos transgenic for pElf5-Ets2iGFP (line 4; “tg”; B–D) or not (E). Cdx2 expression is “rescued” in embryos C, D but not B by
overexpressing Ets2 in an Elf5-like fashion. Constriction (stars) seen in panel B is an artefact. White triangles, EEC; scale bar, 100 mm.
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that such embryos still express Ascl2 (similar to the dosage from
two Elf5 alleles in the Ets2/) but now, in addition, have lost the
tissue between the EEC and the domain of Ascl2 expression. Lastly,
adding more Ets2 via a transgene to an Elf5 deﬁcient embryo adds
sufﬁcient Elf5-like dosage to restore Ascl2 expression. The obser-
vation that the Ets2/ , Elf5/ , Elf5þ/Ets2þ/ and rescue
genotypes all lead to variable phenotypes suggests that the phen-
otypic thresholds for the total Elf5þEts2 dosage are themselves
somewhat variable.
In conclusion, we suggest that Ets2 and Elf5 are partially
redundant with the early ExE phenotype being predominantly
driven by loss of Elf5 activity whereas Ets2 has an additional later
role in the maintenance/survival of the EPC. The (partial) inter-
changeability of these factors may explain the puzzling absence of
ELF5 expression during equivalent stages of cattle trophoblast
development (Pearton et al., 2011) in that ETS2, which is expressed
in cattle peri-gastrulation trophoblast, may be functionally sub-
stituting for the absence of ELF5.
Methods
Mice
Animal procedures were conducted under the approval of the
Ruakura Animal Ethics Committee (RAEC 11183), transgenic work
under ERMA approval GMD003420. Elf5 deﬁcient mice (129 back-
ground) were previously described (Donnison et al., 2005). Ets2
deﬁcient animals (Ets2-db1/þ) were obtained from Dr. Robert
Oshima and backcrossed for 5 generations onto the 129 strain
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Fig. 9. Summary model for trophoblast gene expression indicating the correlation between in vivo and in vitro expression and the effect of Elf5þEts2 dosage: (A) based on
the in vivo E6.5 expression pattern and in vitro differentiation kinetics, we suggest the subdivision of the ExE into two territories: 1, a region proximal to the Epi/ExE border
(PrExE), marked by Cdx2, Sox2 and Spry4 expression (as well as more ubiquitous ExE markers such as Elf5 and Fgfr2), absence of Ascl2 and composed of cells highly
dependent on growth factors, and 2, an ExE region distal to this (DiExE), expressing Elf5, Fgfr2, Ascl2 but not Cdx2, Sox2 or Spry4. The in vitro counterpart, in terms of gene
expression, are TS cells between 6 and 24 h after growth factor removal. The EPC characterised by Ascl2, Ets2 and Plac1 expression is distally delineated by the expression of
Ascl2 which tends to be quite variable. This corresponds to 2–4 days post growth factor removal concurrent with the upregulation of late differentiation markers such as
Secretin. Width of bars on upper graph represent relative levels, small letters on lower graph indicate signiﬁcantly different locations of borders (Student's t-test; Po0.05).
Bottom bars represent mean size of embryonic ectoderm and ExE region in E6.5 embryos measured. Error bars show standard deviations. (B) Correlation of genotype (alleles
of Elf5 and Ets2 and the Elf5-Ets2 construct) on the phenotype as deﬁned in panel (A). Model described in detail in the main text.
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background. Four lines of pElf5-Ets2iGFP overexpressing mice were
generated via pronuclear injection of FvB zygotes according to
established protocols (Nagy et al., 2003). Lines 3 and 4 were bred
for 5 generations into the 129 strain before crossing against Elf5þ/
animals. Animals and embryos were genotyped by PCR. For Elf5,
primers 5, 8, 9 were used for PCR genotyping, GAGCAATGGGAA-
TAAACAGGG (5), GGAGAAAGGTGGGGAGGATAA (8), TGGATGTG-
GAATGTGTGCGA (9), with 5 and 8 yielding an amplicon of 577 bp
for the wild type allele, 5 and 9 a 411 bp product for the targeted
allele. For Ets2, primers 1, 2, 3 were used, GAACAGCCAGTCGTCCCTAC
(1), TGTTCACTTACCAGTGAAGCCA (2), CACACGCGTCACCTTAATATGC
(3), with 1 and 2 yielding a 199 bp wild type, and with 1 and 3 a
283 bp targeted allele, amplicon. pElf5-Ets2iGFP alleles were
detected using GFP primers CCGACCACATGAAGCAGCACGAC and
TCACGAACTCCAGCAGGACCAT. PCR conditions were 95 1C 30 followed
by n cycles of 94 1C 30″, 60 1C 30”, 72 1C 60″ and one cycle of 72 1C for
70, where n¼35 for Elf5 and Ets2 and n¼30 for pElf5-Ets2iGFP.
Ets2 and Elf5 knock-down
TS cells were maintained as previously described (Pearton et al.,
2014). Ets2 was knocked down by a 4 h transfection with 20 pmol
(Ets2si1, CAAACCAGUUAUUCCUGCAGCAGUA) or 50 pmol (Ets2si2,
UAACUGGUUUGCCUUGCUCGACUGG) double stranded stealth RNA
(Invitrogen) using 10 ml Lipofectamine 2000 (Invitrogen) per 4 cm
well in 2 ml reduced serum (4% FCS) TS-medium. Elf5 was knocked
down as previously described (Pearton et al., 2014). The negative
control siRNA was Invitrogen's Medium-GC stealth RNAi. Cells were
recovered 48 h after treatment commencement.
Microarrays
Three (biological repeats) GeneChipMouse Genome 430 2.0 Arrays
(Affymetrix) containing 45,000 different probe sets, each were used
for the Ets2-si1, si2 and control siRNA samples. RNA was harvested
after 48 h treatment. RNA processing, array probing and analysis were
done as previously described for Elf5 knock-down (Pearton et al.,
2014). The data is accessible at NCBI's GEO database, accession
number GSE62168 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc¼GSExxx).
Quantitative PCR
RNA isolation, reverse transcription, real-time PCR and quanti-
tation procedures were performed as detailed previously (Smith
et al., 2007), with modiﬁcations as outlined in Smith et al. (2010).
Transcripts were quantiﬁed relative to the geometric mean of the
three housekeepers (Gapdh, β-actin and β-tubulin) while normal-
ising for the unique ampliﬁcation efﬁciencies of each primer pair.
Each sample was measured in triplicate, one measurement being
of a twofold dilution. Samples not showing halving of copy
number 750% when diluted twofold were deemed to lie outside
the linear range and classiﬁed as below detection. A no template
control, RT-control and dissociation curve analysis were included
in each real-time run. Primer details are shown in Supplementary
Table S2.
WMISH
Whole mount in situ hybridisation (WMISH) was perfor-
med as described (Donnison et al., 2005). Fragments of
Ascl2, Spry4, Plac1 were ampliﬁed by RT-PCR from TS cell
RNA using primers GAGCAACCGAGGCCAGCAGCA and GTTTC-
TTGGGCTAGAAGCAGG (Ascl2), GCTCCTCAAAGACCCCTAGAA and
TTGGGGACTCAAGGCTAGGCA (Spry4) and GAGCACAAAGC-
CACGTTTCAA and TGATGGAGGGTTTACATGCTC (Plac1), cloned into
pGEM-T-Easy using TA-cloning (Promega) and transcribed using
SP6 or T7 RNA polymerase depending on the orientation of
insertion (all primers shown with 50 end on left). Other probes
as described in Donnison et al. (2005) and Pearton et al. (2014).
Where required, embryos were genotyped subsequent to staining
by ﬁrst digesting in 50 μl of Proteinase K solution buffer [100 mM
Tris (pH 8.0), 5 mM EDTA, 0.1% SDS, 200 mM NaCl] at 55 1C for 1 h
while shaking at 900 rpm, boiling the lysate for 5 min, then
performing PCR using 0.5 μl in a 25 μl PCR reaction under
conditions as detailed under section “Mice”.
Immunocytochemistry
Bovine embryonic ﬁbroblast cells (EF5) transfected with pCAG-Ets2-
IRES-GFP, and non-transfected cells, were grown to 80% conﬂuency in
4 cm wells, harvested with 300 μl 2 gel loading buffer, boiled for
4 min and 30 μl loaded onto a 12% Bis/Tris Criterion pre-cast gel (Bio-
Rad) and electrophoresed at 140 V for 2 h. After over-night transfer
(15 V) onto nitrocellulose membrane (Pall Life Sciences), membranes
were blocked with 4% reconstituted non-fat milk powder (in TBS/BSA/
Tween20) for 3 h. Wash 1 for 5 min in TBS, incubate with anti
Ets1þ2 antibody (C-275, #SC-112, Santa Cruz Biotechnology) at
1/10,000 in TBS-BSA-Tween20 for 2 h and goat anti-rabbit (HRP
conjugated, Sigma) at 1/15,000 for 1 h. ECL reagent (25 ml 0.1 M Tris
pH8.6 with 60 μl of 91.7 mg/ml Luminol (Sigma A8511) in DMSO, 10 μl
of 28 mg/ml p-coumaric acid (Sigma 9008) in DMSO and 7.7 μl 30%
H2O2) was added for 2 min and the membrane exposed to X-ray ﬁlm
(Carestream, Biomax XAR) for 1 min.
Construction of pElf5-Ets2iGFP
The building vector for ET-based recombineering (Liu et al., 2003)
was constructed by ﬁrst inserting a XhoI-SpeI fragment containing an
IRES-emGFP-pA cassette between the two 307- and 170-bp Elf5
homology boxes of pElf5-BV-empty. A 1.37 kbp fragment of Ets2
codons ﬂanked by Xho1 and Sal1 restriction sites was generated by
PCR frommouse ExE cDNA using primers GAActcgagG-CGCGATGAAT-
GACTTTGGAAT and GAAgtcgacG-CTGGCTCAGG-GTGGTCCTGA-GGC
and inserted upstream of the IRES using the XhoI site. Recombination
in SW102 cells containing mouse Elf5 BAC RP23-44A14 (125 kbp;
C57Bl/6J strain; CHORI) resulted in the insertion of the Ets2-IRES-GFP
cassette 6 bp downstream from the splice acceptor junction of Elf5
Exon-2, while removing 62 bp comprising the Elf5 start codon. The
Elf5 enhancer region faithfully recapitulating Elf5 expression (con-
struct #9 in Pearton et al., 2011) together with the inserted Ets2-IRES-
GFP-neo cassette (22.9 kbp) was recovered using a pBS based retrieval
vector containing 388 bp (upstream, unique NotI site added) and
394 bp (downstream, over unique ClaI site) Elf5 homology regions
located at the ends of construct #9, using ET-recombineering (Liu
et al., 2003). The construct was veriﬁed by restriction mapping and
sequencing of the modiﬁed regions. The DNA was prepared for
microinjection by gel puriﬁcation of the vector-less 23 kbp fragment
subsequent to NotI, ClaI digestion and cleaned up with a Wizard
system column (Promega), eluting the DNA with injection buffer
(8 mM Tris–HCl, pH 7.5; 0.1 mM EDTA).
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